Login/Sign Up
Doxulip 50 Injection 25 ml is an anti-cancer medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Doxulip 50 Injection 25 ml is primarily used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast). It is also used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children).
Doxulip 50 Injection 25 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis.
Doxulip 50 Injection 25 ml may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, red discoloration of urine, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Doxulip 50 Injection 25 ml. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.
Doxulip 50 Injection 25 ml should be avoided if you are allergic to it or any other components of this medicine. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression, and severe liver disease. Hence, if you have any such conditions, inform your doctor. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause adverse effects. Doxulip 50 Injection 25 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.
Doxulip 50 Injection 25 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. Doxulip 50 Injection 25 ml is also used in the treatment of acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumour, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma
Doxulip 50 Injection 25 ml should be avoided if you are allergic to it. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression and severe liver disease. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause serious adverse effects. Doxulip 50 Injection 25 ml is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Do not stop receiving Doxulip 50 Injection 25 ml without a doctor’s advice, as it can cause serious health conditions. Doxulip 50 Injection 25 ml is known to cause secondary malignancies, tissue necrosis, cardiomyopathy and septic shock in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.
Drug-Drug Interactions: Doxulip 50 Injection 25 ml may interact with CYP3A4 inducers (phenytoin, phenobarbital, rifampicin), CYP3A4 inhibitors (clarithromycin, voriconazole, cyclosporine, chloramphenicol), CYP2D6 inhibitors (bupropion, fluoxetine, paroxetine), CYP2D6 inducers (dexamethasone, corticosterone, haloperidol).
Drug-Food Interactions: Avoid smoking and alcohol consumption.
Drug-Disease Interactions: Inform your doctor if you have cardiac problems, liver or kidney disease.
According to postmarketing reports, juvenile children receiving doxorubicin hydrochloride are at risk of developing late cardiovascular dysfunction. Risk factors include early age during treatment (particularly five years), large cumulative dosages, and receipt of multimodal modality therapy. All pediatric patients who have received doxorubicin hydrochloride should undergo long-term cardiovascular monitoring.
Breast Cancer: Breast cancer is a type of cancer with abnormal growth in the cells of the breast. There are different kinds of breast cancer, such as cancer occurring in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and in the fatty tissue or the fibrous connective tissue within the breast. Symptoms of breast cancer include a lump in the breast, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, a lump or swelling under the arm, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin.
Lymphoma: Lymphoma is a wide word for cancer that develops in lymph system cells. Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) are the two most common kinds. Hodgkin lymphoma is frequently curable.
About Doxulip 50 Injection 25 ml
Doxulip 50 Injection 25 ml is an anti-cancer medicine used in the treatment of cancer. Cancer is a disease where the cells grow abnormally and divide uncontrollably. Doxulip 50 Injection 25 ml is primarily used as adjuvant chemotherapy in women with axillary lymph nodes with involvement resection of breast cancer (abnormal growth in the cells of the breast). It is also used to treat neuroblastoma (cancer that starts in nerve cells and primarily affects children) and Wilms' tumor (a form of kidney cancer that affects children).
Doxulip 50 Injection 25 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, destroying DNA and RNA synthesis.
Doxulip 50 Injection 25 ml may cause certain side effects such as nausea, headache, abdominal pain, loss of appetite, vomiting, dizziness, mouth sores, tiredness, back pain, red discoloration of urine, diarrhea, and pain at the site of injection. Most of these side effects do not require medical attention and gradually resolve over time. However, if the side effects persist, please consult your doctor. A trained healthcare doctor will administer Doxulip 50 Injection 25 ml. So, do not self-administer. Your doctor will decide the dose of the medicine based on your health condition.
Doxulip 50 Injection 25 ml should be avoided if you are allergic to it or any other components of this medicine. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression, and severe liver disease. Hence, if you have any such conditions, inform your doctor. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause adverse effects. Doxulip 50 Injection 25 ml is known to cause embryo-fetal toxicity. Hence, if you are pregnant or breastfeeding, inform your doctor beforehand.
₹15768.6*
MRP ₹19230
18% off
₹16345.5*
MRP ₹19230
15% CB
₹2884.5 cashback(15%)
Free Delivery
With Circle membership
(Inclusive of all Taxes)
This offer price is valid on orders above ₹800. Apply coupon PHARMA10/PHARMA18 (excluding restricted items)
Online payment accepted
Provide Delivery Location
Whats That
Online payment accepted
Product Substitutes
Uses of Doxulip 50 Injection 25 ml
Medicinal Benefits
Doxulip 50 Injection 25 ml contains Doxorubicin, which belongs to the class of anthracycline topoisomerase inhibitors. It inhibits the topoisomerase II enzyme by intercalating the DNA base pairs. This causes double helix DNA to be uncoiled, thereby destroying the DNA and RNA synthesis. Doxulip 50 Injection 25 ml is also used in the treatment of acute lymphoblastic leukaemia, acute myeloblastic leukaemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumour, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma
Side Effects of Doxulip 50 Injection 25 ml
Directions for Use
Storage
Drug Warnings
Doxulip 50 Injection 25 ml should be avoided if you are allergic to it. It is contraindicated in patients having severe myocardial insufficiency, a recent history of myocardial infarction (MI), severe persistent drug-induced myelosuppression and severe liver disease. Hence avoid using this medicine under such conditions. Inform your doctor if you have any cardiovascular conditions, liver/kidney disease, or taking any CYP3A4 or CYP2D6 inducers medication, as it can cause serious adverse effects. Doxulip 50 Injection 25 ml is known to cause embryo-fetal toxicity. Hence it is contraindicated in pregnant or breastfeeding women. Do not stop receiving Doxulip 50 Injection 25 ml without a doctor’s advice, as it can cause serious health conditions. Doxulip 50 Injection 25 ml is known to cause secondary malignancies, tissue necrosis, cardiomyopathy and septic shock in some patients. Hence careful monitoring of the patient is needed while receiving the medicine.
Therapeutic Class
Drug-Drug Interactions Checker List
Diet & Lifestyle Advise
Habit Forming
Special Advise
According to postmarketing reports, juvenile children receiving doxorubicin hydrochloride are at risk of developing late cardiovascular dysfunction. Risk factors include early age during treatment (particularly five years), large cumulative dosages, and receipt of multimodal modality therapy. All pediatric patients who have received doxorubicin hydrochloride should undergo long-term cardiovascular monitoring.
Disease/Condition Glossary
Breast Cancer: Breast cancer is a type of cancer with abnormal growth in the cells of the breast. There are different kinds of breast cancer, such as cancer occurring in lobules (glands that produce milk), ducts of the breast (the pathway that brings milk from glands to the nipple), and in the fatty tissue or the fibrous connective tissue within the breast. Symptoms of breast cancer include a lump in the breast, breast pain, redness, swelling, nipple discharge other than breast milk, bloody discharge, a lump or swelling under the arm, unexplained change in shape, size or appearance of the breast, peeling, flaking or scaling of the skin.
Lymphoma: Lymphoma is a wide word for cancer that develops in lymph system cells. Hodgkin lymphoma and non-Hodgkin lymphoma (NHL) are the two most common kinds. Hodgkin lymphoma is frequently curable.